Jundishapur Journal of Microbiology

Published by: Kowsar

Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology

Mohammad Hossein Morowvat 1 , 2 , Valiollah Babaeipour 3 , 4 , * , Hamid Rajabi Memari 5 and Hossein Vahidi 1
Authors Information
1 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Biochemical Engineering Group, Biotechnology Research Center, Malek-Ashtar University of Technology, Tehran, IR Iran
4 Department of Bioscience Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, IR Iran
5 Department of Agronomy and Plant Breeding, College of Agriculture, Shahid Chamran University of Ahvaz, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: April 01, 2015, 8 (4); e16236
  • Published Online: April 18, 2015
  • Article Type: Research Article
  • Received: November 18, 2013
  • Revised: July 20, 2014
  • Accepted: August 6, 2014
  • DOI: 10.5812/jjm.8(4)2015.16236

To Cite: Morowvat M H, Babaeipour V, Rajabi Memari H, Vahidi H. Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology, Jundishapur J Microbiol. 2015 ; 8(4):e16236. doi: 10.5812/jjm.8(4)2015.16236.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Elco CP, Sen GC. Encyclopedia of Biological Chemistry. 2013; : 619-23
  • 2. Larocque L, Bliu A, Xu R, Diress A, Wang J, Lin R, et al. Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol. 2011; 2011: 174615[DOI][PubMed]
  • 3. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012; 135(1): 44-53[DOI][PubMed]
  • 4. Sottini A, Capra R, Serana F, Chiarini M, Caimi L, Imberti L. Interferon-beta therapy monitoring in multiple sclerosis patients. Endocr Metab Immune Disord Drug Targets. 2009; 9(1): 14-28[PubMed]
  • 5. Lim SY, Constantinescu CS. Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract. 2010; 64(5): 637-50[DOI][PubMed]
  • 6. Ahn SH, Lee HW, Kim YS, Kim JK, Han KH, Chon CY, et al. Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. Gut Liver. 2009; 3(1): 20-5[DOI][PubMed]
  • 7. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, et al. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43(2): 270-4[PubMed]
  • 8. van Holten J, Plater-Zyberk C, Tak PP. Interferon-beta for treatment of rheumatoid arthritis? Arthritis Res. 2002; 4(6): 346-52[PubMed]
  • 9. Toporovski R, Morrow MP, Weiner DB. Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther. 2010; 10(10): 1489-500[DOI][PubMed]
  • 10. Bracci L, La Sorsa V, Belardelli F, Proietti E. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev Vaccines. 2008; 7(3): 373-81[DOI][PubMed]
  • 11. Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2006; 72(2): 211-22[DOI][PubMed]
  • 12. Tripathi N, Sathyaseelan K, Jana AM, Rao PVL. High Yield Production of Heterologous Proteins with Escherichia coli. Defence Sci J. 2009; 59(2): 137-46[DOI]
  • 13. Swartz JR. Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol. 2001; 12(2): 195-201[PubMed]
  • 14. DeLisa MP, Valdes JJ, Bentley WE. Quorum signaling via AI-2 communicates the "Metabolic Burden" associated with heterologous protein production in Escherichia coli. Biotechnol Bioeng. 2001; 75(4): 439-50[PubMed]
  • 15. Valgepea K, Adamberg K, Nahku R, Lahtvee PJ, Arike L, Vilu R. Systems biology approach reveals that overflow metabolism of acetate in Escherichia coli is triggered by carbon catabolite repression of acetyl-CoA synthetase. BMC Syst Biol. 2010; 4: 166[DOI][PubMed]
  • 16. Wolfe AJ. The acetate switch. Microbiol Mol Biol Rev. 2005; 69(1): 12-50[DOI][PubMed]
  • 17. Eiteman MA, Altman E. Overcoming acetate in Escherichia coli recombinant protein fermentations. Trends Biotechnol. 2006; 24(11): 530-6[DOI][PubMed]
  • 18. Zhang J, Greasham R. Chemically defined media for commercial fermentations. Appl Microbiol Biotech. 1999; 51(4): 407-21[DOI]
  • 19. Shojaosadati SA, Varedi Kolaeil SM, Babaeipour V, Farnoud AM. Recent advances in high cell density cultivation for production of recombinant protein. Iranian J Biotech. 2008; 6(2): 63-84
  • 20. Caspeta L, Flores N, Perez NO, Bolivar F, Ramirez OT. The effect of heating rate on Escherichia coli metabolism, physiological stress, transcriptional response, and production of temperature-induced recombinant protein: a scale-down study. Biotechnol Bioeng. 2009; 102(2): 468-82[DOI][PubMed]
  • 21. Ferreira SL, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC, et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta. 2007; 597(2): 179-86[DOI][PubMed]
  • 22. Maldonado LM, Hernandez VE, Rivero EM, Barba de la Rosa AP, Flores JL, Acevedo LG, et al. Optimization of culture conditions for a synthetic gene expression in Escherichia coli using response surface methodology: the case of human interferon beta. Biomol Eng. 2007; 24(2): 217-22[DOI][PubMed]
  • 23. Tabandeh F, Khodabandeh M, Yakhchali B, Habib-Ghomi H, Shariati P. Response surface methodology for optimizing the induction conditions of recombinant interferon beta during high cell density culture. Chem Eng Sci. 2008; 63(9): 2477-83[DOI]
  • 24. Morowvat MH, Babaeipour V, Rajabi-Memari H, Vahidi H, Maghsoudi N. Overexpression of Recombinant Human Beta Interferon (rhINF-beta) in Periplasmic Space of Escherichia coli. Iran J Pharm Res. 2014; 13: 151-60[PubMed]
  • 25. Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008; 76(5): 965-77[DOI][PubMed]
  • 26. Ferreira SL, Bruns RE, da Silva EG, Dos Santos WN, Quintella CM, David JM, et al. Statistical designs and response surface techniques for the optimization of chromatographic systems. J Chromatogr A. 2007; 1158(1-2): 2-14[DOI][PubMed]
  • 27. Box GEP, Behnken DW. Some New Three Level Designs for the Study of Quantitative Variables. Technometrics. 1960; 2(4): 455-75[DOI]
  • 28. Kaiser S, Verza SG, Moraes RC, Pittol V, Peñaloza EMC, Pavei C, et al. Extraction optimization of polyphenols, oxindole alkaloids and quinovic acid glycosides from cat's claw bark by Box–Behnken design. Ind Crop Prod. 2013; 48: 153-61[DOI]
  • 29. Kumar A, Prasad B, Mishra I M. Process Parametric Study for Ethene Carboxylic Acid Removal onto Powder Activated Carbon using Box-Behnken Design. Chem Eng Tech. 2007; 30(7): 932-7[DOI]
  • 30. Zolgharnein J, Shahmoradi A, Ghasemi JB. Comparative study of Box-Behnken, central composite, and Doehlert matrix for multivariate optimization of Pb (II) adsorption ontoRobiniatree leaves. Chemometrics J. 2013; 27(1-2): 12-20[DOI]
  • 31. Vásquez-Bahena JM, Vega-Estrada J, Santiago-Hernández JA, Ortega-López J, Flores-Cotera LB, Montes-Horcasitas MC, et al. Expression and improved production of the soluble extracellular invertase from Zymomonas mobilis in Escherichia coli. Enzyme Microb Tech. 2006; 40(1): 61-6[DOI]
  • 32. Peng L, Xu Z, Fang X, Wang F, Cen P. High-level expression of soluble human β-defensin-2 in Escherichia coli. Process Biochem. 2004; 39(12): 2199-205[DOI]
  • 33. Yildir C, Önsan ZI, Kirdar B. Optimization of starting time and period of induction and inducer concentration in the production of the restriction enzyme EcoRI from recombinant Escherichia coli 294. Turk Chem J. 1998; 22(3): 221-6
  • 34. Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K, et al. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact. 2008; 7: 11[DOI][PubMed]
  • 35. Azaman SNA, Ramanan RN, Tan JS, Rahim RA, Abdullah MP, Ariff AB. Screening for the optimal induction parameters for periplasmic producing interferon-α2b in Escherichia coli. Afr J Biotechnol. 2010; 9(38): 6345-54
  • 36. Donovan RS, Robinson CW, Glick BR. Review: optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. J Ind Microbiol. 1996; 16(3): 145-54[PubMed]
  • 37. Mergulhao FJ, Monteiro GA. Analysis of factors affecting the periplasmic production of recombinant proteins in Escherichia coli. J Microbiol Biotechnol. 2007; 17(8): 1236-41[PubMed]
  • 38. Shiloach J, Rinas U. 2009; : 377-400[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments